David S. Mendelson

Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer

Roy S. Herbst, S. Gail Eckhardt, Razelle Kurzrock et al. · Journal of Clinical Oncology · 2010 · 440 citations

Life Sciences, Oncology, Pharmacology +17

Phase I Clinical Study of Pertuzumab, a Novel HER Dimerization Inhibitor, in Patients With Advanced Cancer

David B. Agus, Michael S. Gordon, Charles Taylor et al. · Journal of Clinical Oncology · 2005 · 388 citations · Full text

Medicine, Oncology, Pharmacology +7

A Roadmap for Foundational Research on Artificial Intelligence in Medical Imaging: From the 2018 NIH/RSNA/ACR/The Academy Workshop

Curtis P. Langlotz, Bibb Allen, Bradley J. Erickson et al. · Radiology · 2019 · 366 citations · Full text

Computing, Computer Science, Radiology +17

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Shanu Modi, Alison Stopeck, Michael S. Gordon et al. · Journal of Clinical Oncology · 2007 · 334 citations

Medicine, Pharmacology, Pharmacotherapy +15

Pulmonary Nontuberculous Mycobacterial Disease, Ontario, Canada, 1998–2010

Theodore K. Marras, David S. Mendelson, Alex Marchand‐Austin et al. · Emerging infectious diseases · 2013 · 219 citations · Full text

Veterinary Medicine, Infectious Diseases, Microbiology +10